Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Tax Provisions (2022 - 2025)

Atara Biotherapeutics' Tax Provisions history spans 4 years, with the latest figure at $28000.0 for Q3 2025.

  • For Q3 2025, Tax Provisions rose 264.71% year-over-year to $28000.0; the TTM value through Dec 2025 reached $31000.0, up 358.33%, while the annual FY2025 figure was $31000.0, 358.33% up from the prior year.
  • Tax Provisions reached $28000.0 in Q3 2025 per ATRA's latest filing, up from $3000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $28000.0 in Q3 2025 to a low of -$19000.0 in Q3 2023.
  • Average Tax Provisions over 4 years is $4181.8, with a median of $3000.0 recorded in 2025.
  • The largest YoY upside for Tax Provisions was 450.0% in 2023 against a maximum downside of 290.0% in 2023.
  • A 4-year view of Tax Provisions shows it stood at $2000.0 in 2022, then surged by 450.0% to $11000.0 in 2023, then crashed by 272.73% to -$19000.0 in 2024, then skyrocketed by 247.37% to $28000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Tax Provisions are $28000.0 (Q3 2025), $3000.0 (Q2 2025), and -$19000.0 (Q4 2024).